Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach.
Saved in:
| Title: | Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach. |
|---|---|
| Authors: | Overgaard RV; Novo Nordisk A/S, Søborg, Denmark., Birkhan O; Novo Nordisk A/S, Søborg, Denmark., Rathor N; Novo Nordisk A/S, Søborg, Denmark., Sparsø T; Novo Nordisk A/S, Søborg, Denmark., Strathe A; Novo Nordisk A/S, Søborg, Denmark., Wharton S; University of Toronto, York University, McMaster University, Wharton Weight Management Clinic, Burlington, Ontario, Canada., Rubino D; Washington Center for Weight Management and Research, Arlington, Virginia, USA. |
| Source: | Diabetes, obesity & metabolism [Diabetes Obes Metab] 2026 Jul; Vol. 28 (7), pp. 5982-5991. Date of Electronic Publication: 2026 Apr 23. |
| Publication Type: | Journal Article; Comparative Study |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
